ArticleMethods in molecular biology (Clifton, N.J.)2026
Computational Methods for Cancer Neoantigen Prediction.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoantigens are mutated peptides arising from tumor genomic alterations, which can be recognized and attacked by the immune system, leading to antitumor immune responses. In the last decades, many immunotherapeutic strategies have been developed, which has increased the interest in neoantigens. This led to the development of computational tools that facilitate neoantigen identification and prioritization, prior to their validation using experimental approaches. This chapter aims at explaining the key steps that need to be conducted to identify potential neoantigens in silico, including an example of the most frequently used tools. This is followed by a description and comparison of the cutting-edge tools and pipelines for neoantigen prediction both for human and mouse. The last aim of this chapter is to depict the technical challenges that limit neoantigen prediction using bioinformatics, as well as the expected improvements, given the current revolution of artificial intelligence, which is implemented in most of the neoantigen-related tools. As exposed in this book chapter, we believe that advances in immunomics and computational biology will be key to implement personalized cancer immunotherapy in the clinical practice, to improve outcomes of cancer patients.
Indexed as
Identifiers
41028271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.